Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bearish -45

Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth

AI-generated analysis

📉 Abbott Laboratories (ABT) shares fell after Jensen Investment Management highlighted guidance cuts and litigation concerns overshadowing growth.

📊 The company lowered full-year guidance to reflect share dilution from the Exact Sciences acquisition.

⚠️ Ongoing uncertainty regarding NEC litigation over preterm infant formula continues to weigh on investor sentiment.

📈 Medical Devices and Established Pharma segments delivered high-single-digit organic growth, representing over 62% of Q1 sales.

🏥 Nutrition and portions of the Diagnostics business faced near-term headwinds impacting overall performance.

📉 Jensen Quality Growth Equity Strategy returned 10.94% in Q2 2026, trailing the S&P 500's 15.20% gain.

🔍 Abbott is not currently on Jensen's list of top AI or monopoly stocks for higher return potential.

📉 Hedge fund holdings in Abbott decreased slightly to 73 portfolios at the end of Q1 2026 from 71 previously.

💰 Abbott closed at $103.06 per share on July 24, 2026, with a market cap of approximately $179.51 billion.

📉 The stock lost 18.43% over the past 52 weeks despite a one-month return of 7.04%.

Bullish Signals
  • Medical Devices and Established Pharma segments achieved high-single-digit organic growth, driving revenue in areas representing over 62% of Q1 sales.
  • The company maintains a substantial market capitalization of approximately $179.51 billion with a trading range between $81.97 and $137.49.
Risk Factors
  • Management lowered full-year guidance to reflect dilution from the Exact Sciences acquisition.
  • Select businesses, including Nutrition and portions of Diagnostics, experienced near-term headwinds.
  • Ongoing uncertainty surrounding NEC litigation related to preterm infant formula continues to weigh on investor sentiment.
  • The stock price declined following Q1 earnings, detracting from Jensen Investment Management's portfolio performance.
Full Analysis
Abbott Laboratories (NYSE: ABT) shares declined following the release of Jensen Investment Management's second-quarter 2026 investor letter. The asset management firm, which returned 10.94% in Q2 2026, noted that Abbott detracted from its portfolio performance during the quarter due to a stock price drop after first-quarter earnings and lowered full-year guidance. Management reduced its outlook primarily to account for dilution resulting from the Exact Sciences acquisition. Additionally, specific business segments, including Nutrition and portions of Diagnostics, faced near-term headwinds that impacted overall growth prospects despite strong underlying performance in other areas. The stock also experienced pressure from ongoing legal uncertainty surrounding litigation related to preterm infant formula (NEC). These combined factors overshadowed otherwise robust results, specifically high-single-digit organic growth recorded in the Medical Devices and Established Pharma segments, which collectively account for over 62% of Q1 sales. Jensen Investment Management currently does not rank Abbott among its top AI or monopoly stock picks, citing a belief that certain artificial intelligence stocks offer higher return potential within shorter timeframes. The fund holds 73 hedge fund portfolios in Abbott as of the end of the first quarter, down slightly from the previous quarter's count of 71.